Pfizer Competitors and Similar CompaniesClear all
Merck's competitors and similar companies include Bausch Health, Astellas Pharma, Boehringer Ingelheim, Merck Group, Sanofi, Takeda, Amgen, Bristol Myers Squibb, Bayer, GSK and Lilly.
 Merck Merck (also known as MSD) is a company that develops and manufactures medicines and vaccines for human and animal health. |  Bausch Health Bausch Health is a company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Boehringer Ingelheim Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products. | |||
Founding Date | Founding Date 1891 | Founding Date 1959 | Founding Date 1923 | Founding Date 1958 | Founding Date 1668 | Founding Date 1994 | Founding Date 1781 | Founding Date 1980 | Founding Date 1887 | Founding Date 1863 | Founding Date 2000 | Founding Date 1876 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Rahway, US HQ Munro, AR Macquarie Park, AU Krems An Der Donau, AT Wien, AT Bruxelles, BE Santa Cruz De La Sierra, BO see more | Locations Laval, CA HQ Buenos Aires, AR Wien, AT Sarajevo, BA Indaiatuba, BR Porto Alegre, BR Sao Paulo, BR see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Ingelheim am Rhein, DE HQ Ouled Fayet, DZ Munro, AR Macquarie Park, AU Wien, AT Minsk, BY Bruxelles, BE see more | Locations Darmstadt, DE HQ Buenos Aires, AR Bayswater, AU Macquarie Park, AU Wien, AT Hoeilaart, BE Rio De Janeiro, BR see more | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more | ||
Employees | Employees 73,0004% increase | Employees 20,700 | Employees 14,754 | Employees 1,2338% increase | Employees 62,34615% decrease | Employees 82,878 | Employees 47,4554% decrease | Employees 25,200 | Employees 34,100 | Employees 88,5021% decrease | Employees 68,629 | Employees 47,0009% increase |
Valuation ($) | Valuation ($) 294.7 b | Valuation ($) 3 b | Valuation ($) 20.8 b | Valuation ($) N/A | Valuation ($) 71.6 b | Valuation ($) 141.1 b | Valuation ($) 43.7 b | Valuation ($) 170.4 b | Valuation ($) 97.8 b | Valuation ($) 27.1 b | Valuation ($) 862.5 m | Valuation ($) 903.4 b |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $65b (FY, 2025) | Revenue (est.) $10.3b (FY, 2025) | Revenue (est.) ¥2.1t (FY, 2026) | Revenue (est.) €12.7b (FY, 2023) | Revenue (est.) €21.1b (FY, 2025) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) ¥4.5t (FY, 2026) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $48.2b (FY, 2025) | Revenue (est.) €45.6b (FY, 2025) | Revenue (est.) £32.7b (FY, 2025) | Revenue (est.) $65.2b (FY, 2025) |
Cost of goods | Cost of goods $16.4b (FY, 2025) | Cost of goods $1.7b (FY, 2025) | Cost of goods ¥213.8b (FY, 2026) | Cost of goods €4b (FY, 2023) | Cost of goods €6.5b (FY, 2025) | Cost of goods €11.6b (FY, 2025) | Cost of goods ¥850.5b (FY, 2026) | Cost of goods $12b (FY, 2025) | Cost of goods $13.9b (FY, 2025) | Cost of goods €14b (FY, 2025) | Cost of goods £5.6b (FY, 2025) | Cost of goods $11.1b (FY, 2025) |
Gross profit | Gross profit $48.6b (FY, 2025) | Gross profit $8.5b (FY, 2025) | Gross profit ¥2t (FY, 2026) | Gross profit €8.7b (FY, 2023) | Gross profit €15b (FY, 2025) | Gross profit €37.6b (FY, 2025) | Gross profit ¥3.7t (FY, 2026) | Gross profit $24.7b (FY, 2025) | Gross profit $34.3b (FY, 2025) | Gross profit €32.5b (FY, 2025) | Gross profit £28.5b (FY, 2025) | Gross profit $54.1b (FY, 2025) |
Net income | Net income $18.3b (FY, 2025) | Net income $120m (FY, 2025) | Net income ¥291.6b (FY, 2026) | Net income €5.8b (FY, 2023) | Net income €2.6b (FY, 2025) | Net income €8b (FY, 2025) | Net income ¥192b (FY, 2026) | Net income $7.7b (FY, 2025) | Net income $7.1b (FY, 2025) | Net income (€3.6b) (FY, 2025) | Net income £6.3b (FY, 2025) | Net income $20.6b (FY, 2025) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 66 (FY, 2021) | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries N/A | Countries 83 (FY, 2021) | Countries 92 (FY, 2021) | Countries 120 (FY, 2021) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities 37 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 8 (FY, 2021) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products 27 (FY, 2019) |
Phase I Trials Products (Immunology) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 1 (Oct, 2020) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 6 (FY, 2021) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products 85 (FY, 2022) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 8 (FY, 2021) |
Phase II Trials Products (Immunology) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 1 (Oct, 2020) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 6 (FY, 2021) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products 32 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 10 (FY, 2021) |
Phase III Trials Products (Immunology) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 1 (Oct, 2020) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 3 (FY, 2021) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products 1.4 k (FY, 2019) | Products N/A | Products 73 (Feb, 2024) | Products 300 k (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 225 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers 23 (FY, 2019) | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 11 (FY, 2021) | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 93.8 k (FY, 2021) | Suppliers 37.5 k (FY, 2021) | Suppliers N/A |
Trademarks | Trademarks N/A | Trademarks 170 (Feb, 2021) | Trademarks N/A | Trademarks 5.2 k (Feb, 2024) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks 1.5 k (FY, 2021) | Trademarks N/A | Trademarks N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 121m | Total funding raised $ 310m | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised $ 3.5b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Bausch Health
HQ
Laval, CA
Employees
20,700
Bausch Health is a company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products.
View companyAstellas Pharma
HQ
Tokyo, JP
Employees
14,754
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
View companyBoehringer Ingelheim
HQ
Ingelheim am Rhein, DE
Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing.
View company
Merck Group
HQ
Darmstadt, DE
Employees
62,346↓ 15% decrease
Merck Group is a company that offers science and technology services.
View company